Search results for "Drug Administration Routes"

showing 5 items of 15 documents

The rewarding effects of ethanol are modulated by binge eating of a high-fat diet during adolescence

2017

Abstract Binge-eating is considered a specific form of overeating characterized by intermittent and high caloric food intake in a short period of time. Epidemiologic studies support a positive relation between the ingestion of fat and ethanol (EtOH), specifically among adolescent subjects. The aim of this work was to clarify the role of the compulsive, limited and intermittent intake of a high-fat food during adolescence on the rewarding effects of EtOH. After binge-eating for 2 h, three days a week from postnatal day (PND) 29, the reinforcing effects of EtOH were tested with EtOH self-administration (SA), conditioned place preference (CPP) and ethanol locomotor sensitization procedures in …

Maleendocrine systemmedicine.medical_specialtyTime FactorsSelf AdministrationNucleus accumbensDiet High-FatMice03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineRewardInternal medicinemental disordersmedicineAnimalsIngestionBulimiaOvereatingreproductive and urinary physiologyPharmacologyEthanolBinge eatingDrug Administration RoutesCentral Nervous System DepressantsConditioned place preference030227 psychiatryVentral tegmental areaDisease Models Animalmedicine.anatomical_structureEndocrinologyAnimals NewbornAnesthesiaConditioning Operantmedicine.symptomμ-opioid receptorSelf-administrationPsychologyLocomotion030217 neurology & neurosurgeryNeuropharmacology
researchProduct

Release of naltrexone on buccal mucosa: Permeation studies, histological aspects and matrix system design

2007

Transbuccal drug delivery has got several well-known advantages especially with respect to peroral way. Since a major limitation in buccal drug delivery could be the low permeability of the epithelium, the aptitude of NLX to penetrate the mucosal barrier was assessed. Ex vivo permeation across porcine buccal mucosa 800 microm thick was investigated using Franz type diffusion cells and compared with in vitro data previously obtained by reconstituted human oral epithelium 100 microm thick. Both fluxes (Js) and permeability coefficients (K(p)) are in accordance, using either buffer solution simulating saliva or natural human saliva. Permeation was evaluated also in presence of chemical enhance…

Naltrexone HydrochlorideTime FactorsSpectrophotometry InfraredSwineChemistry PharmaceuticalNarcotic AntagonistsPharmaceutical SciencePharmacologyDosage formDrug Delivery SystemsFormaldehydeAnimalspermeation studieNLXIontophoresisChemistryNarcotic antagonistDrug Administration RoutesMouth MucosaAdministration Buccalsystem design.General MedicineBuccal administrationIontophoresisPermeationmatrixKineticsbuccal mucoDrug deliveryhistological aspectnaltrexoneTabletsBiotechnologyEuropean Journal of Pharmaceutics and Biopharmaceutics
researchProduct

Evidence of a flip-flop phenomenon in acamprosate pharmacokinetics: an in vivo study in rats.

2006

The pharmacokinetics of acamprosate were examined in the rat after oral and intravenous administration in order to detect the possible presence of a flip-flop phenomenon. Rats received 9.3 or 73.3 mg/kg of the drug as an intravenous bolus. The same doses were orally administered via gastric intubation. Plasma samples were taken from the jugular vein for determination of acamprosate concentration by liquid scintillation counting. The drug content was also quantified in urine and faeces. The acamprosate bioavailability was close to 20%, the amount recovered in the faeces being around 80% of the administered dose. The terminal slope of the oral plasma curve was significantly lower than that ob…

PharmacologyMaleDose-Response Relationship DrugChemistryTaurineAcamprosateDrug Administration RoutesPharmaceutical ScienceGeneral MedicineAbsorption (skin)UrinePharmacologyBioavailabilityRatsDose–response relationshipAcamprosatePharmacokineticsIn vivoOral administrationmedicineAnimalsPharmacology (medical)Rats Wistarmedicine.drugAlcohol DeterrentsBiopharmaceuticsdrug disposition
researchProduct

Development of extracellular vesicle-based medicinal products: A position paper of the group “Extracellular Vesicle translatiOn to clinicaL perspecti…

2021

International audience; Extracellular vesicles (EV) are emergent therapeutic effectors that have reached clinical trial investigation. To translate EV-based therapeutic to clinic, the challenge is to demonstrate quality, safety, and efficacy, as required for any medicinal product. EV research translation into medicinal products is an exciting and challenging perspective. Recent papers, provide important guidance on regulatory aspects of pharmaceutical development, defining EVs for therapeutic applications and critical considerations for the development of potency tests. In addition, the ISEV Task Force on Regulatory Affairs and Clinical Use of EV-based Therapeutics as well as the Exosomes C…

Quality ControlKnowledge management[SDV.BIO]Life Sciences [q-bio]/BiotechnologyBiological medicinal productsmedia_common.quotation_subjectDrug Compounding[SDV]Life Sciences [q-bio]Regulatory requirementsPharmaceutical ScienceMarketing authorizationExosomesChemistry Techniques Analytical03 medical and health sciencesExtracellular Vesicles0302 clinical medicineDrug DevelopmentDrug Stability[CHIM]Chemical SciencesHumansQuality (business)ComputingMilieux_MISCELLANEOUS030304 developmental biologymedia_commonCell-free therapySecretome0303 health sciencesClinical Trials as TopicClinical-grade EVScientific progressbusiness.industryDrug Administration RoutesExtracellular vesicleDrugs InvestigationalRegulatory affairs3. Good health[SDV.BIO] Life Sciences [q-bio]/BiotechnologyClinical trialEuropeAnalytics030220 oncology & carcinogenesisPosition paperMedicinal productsBusinessMicrovesicles
researchProduct

The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing.

2011

Breakthrough cancer pain (BTcP) has been defined as a transitory increase in pain intensity on a baseline pain of moderate intensity in patients on analgesic treatment regularly administered. This review provides updated information about the use of opioids for the treatment of BTcP, with special emphasis on the use of new rapid onset opioids (ROOs). Due to its slow onset to effect oral opioids cannot be considered an efficacious treatment for BTcP. Parenteral opioids may provide rapid onset of analgesia, but not always available particularly at home. Different technologies have been developed to provide fast pain relief with potent opioid drugs such fentanyl, delivered by non-invasive rout…

business.industryDrug Administration RoutesAnalgesicBreakthrough PainHematologyBuccal administrationPlaceboFentanylAnalgesics OpioidOncologyOpioidAnesthesiaNeoplasmsmedicineHumansPain ManagementNasal administrationDosingCancer painbusinessmedicine.drugCritical reviews in oncology/hematology
researchProduct